Nippon Medical School- Tohoku University Graduate School Intervention with Pitavastatin: Study for hypercholesterolemia with type 2 diabetes mellitus.

INTERVENTION: Pitavastatin 1 mg or 2 mg daily for a period of 36 months Pravastatin 10 mg daily for a period of 36 months CONDITION: Hypercholesterolemic patients with type 2 diabetes mellitus PRIMARY OUTCOME: A change of intima‐media thickness (IMT)of common carotid artery SECONDARY OUTCOME: A change of the following items; (1)Serum lipid profile (LDL‐C, triglyceride, HDL‐C); (2)Atherosclerosis‐related markers (adiponectin, hsCRP, PCOOH, urinary 8‐OH‐dG); (3)LPL mass; (4)Plasma glucose (fasting plasma glucose, HbA1c); (5)Microalbuminuria; Evaluation of adverse events and laboratory test abnormalities INCLUSION CRITERIA: Patients who (1)are treated with diet, exercise and/or medication for at least 8 weeks, with HbA1c < 8.0% (a percent change to be =/< +/‐10%) at last 2 measurements. (2)have Hypercholesterolemia with fasting level of serum LDL‐C >/= 140 mg/dL (by the Friedewald formula) at measurements in the run‐in period. (3)have fasting serum levels of triglyceride < 400 mg/dL. (4)are diagnosed with type 2 diabetes. (5)are at age of 20 to 75 years at time of consent. (6)male or female (7)provide written informed concent for participation in the study voluntarily after being fully informed and explained.